PHR1 Antibody

What is PHR1 and why is it important in research?

PHR1 represents two distinct proteins depending on the research context. In plants, PHR1 (Phosphate Starvation Response 1) functions as a key transcription factor that regulates phosphate signaling and homeostasis. It directly modulates the expression of PHOSPHATE1 (PHO1), PHOSPHATE TRANSPORTER1 (PHT1), and other genes involved in phosphate uptake and redistribution . In mammals, PHR1 is a synonym for MYCBP2, which encodes MYC binding protein 2 and functions in axon guidance and protein ubiquitination. The human version has 4678 amino acids with a molecular mass of 513.6 kilodaltons and exists in two isoforms, localizing to both the nucleus and cytoplasm . Research on both plant and mammalian PHR1 is valuable for understanding fundamental biological processes related to nutrient sensing, signaling pathways, and cellular responses to environmental stresses.

What are the primary applications for PHR1 antibodies?

PHR1 antibodies are primarily used in Western blot (WB) and ELISA applications to detect and quantify PHR1 protein in biological samples . In Western blot applications, these antibodies allow researchers to determine PHR1 protein expression levels, post-translational modifications, and protein-protein interactions in various experimental conditions. ELISA applications provide quantitative measurement of PHR1 levels. The specific applications vary depending on whether you're working with plant or mammalian systems, with plant PHR1 antibodies particularly useful for studying phosphate starvation responses, while mammalian PHR1/MYCBP2 antibodies help investigate neuronal development and protein ubiquitination pathways.

How do I select the appropriate PHR1 antibody for my research?

Selecting the appropriate PHR1 antibody requires consideration of several factors:

• Species reactivity: Ensure the antibody recognizes your target species. For plant research, determine if you need antibodies specific to monocots (like barley, with expected MW of 33 kDa) or dicots (like Arabidopsis thaliana). For mammalian research, check reactivity with human, mouse, or rat samples .

• Application compatibility: Verify the antibody has been validated for your intended application (Western blot, ELISA, immunohistochemistry, etc.) .

• Antibody type: Consider whether a polyclonal antibody (offering broader epitope recognition) or monoclonal antibody (providing higher specificity) better suits your experimental needs.

• Immunogen information: Review the immunogen used to generate the antibody to ensure it will detect the relevant domain or isoform of PHR1 in your experimental system .

• Validation data: Examine available validation data, including expected band sizes in Western blots, to confirm specificity and performance in your experimental system.

What controls should I include when using PHR1 antibodies?

When working with PHR1 antibodies, implement these essential controls:

• Positive control: Include samples known to express PHR1, such as:

  • For plant PHR1: Wild-type Arabidopsis or barley tissue under phosphate starvation conditions

  • For mammalian PHR1/MYCBP2: Neural tissue or cell lines with known expression

• Negative control: Include samples where PHR1 is absent or at minimal levels:

  • For plants: phr1 mutant tissue or non-stressed tissue

  • For mammals: Tissues or cell lines with low MYCBP2 expression

• Loading control: Use housekeeping proteins (actin, tubulin, GAPDH) to normalize protein loading.

• Antibody controls:

  • Primary antibody omission control

  • Secondary antibody-only control to detect non-specific binding

  • Blocking peptide competition assay to confirm specificity

• Recombinant protein control: If available, include purified recombinant PHR1 protein as shown in application examples where MBP-tagged PHR1 is used .

How can I optimize Western blot protocols for PHR1 detection?

Optimizing Western blot protocols for PHR1 detection requires careful attention to several parameters:

• Sample preparation:

  • For plant samples: Use extraction buffers containing phosphatase inhibitors, as PHR1 is known to be regulated by phosphorylation

  • For mammalian samples: Consider using RIPA buffer with protease inhibitors for MYCBP2/PHR1 extraction

• Gel percentage selection:

  • For plant PHR1 (~33 kDa): Use 10-12% SDS-PAGE gels

  • For mammalian MYCBP2/PHR1 (513.6 kDa): Use 6-8% gels or gradient gels (4-15%)

• Transfer conditions:

  • For smaller plant PHR1: Standard semi-dry transfer for 1 hour as demonstrated in the application example

  • For large mammalian MYCBP2/PHR1: Extended wet transfer (overnight at low voltage) with SDS in transfer buffer

• Blocking conditions:

  • Use 5-10% milk or BSA in TBS-T for 1 hour at room temperature

  • Test both to determine optimal blocking agent

• Antibody dilution and incubation:

  • Primary antibody: Start with manufacturer's recommended dilution (typically 1:1000 for Western blot)

  • Secondary antibody: Typically use 1:50,000 dilution of HRP-conjugated secondary antibodies

• Detection method:

  • For low abundance PHR1, use enhanced chemiluminescence (ECL) detection systems

  • Consider testing more sensitive ECL substrates if detection is challenging

What are the key methodological considerations for studying PHR1 in phosphate signaling pathways?

When investigating PHR1's role in phosphate signaling pathways, consider these methodological approaches:

• Experimental design for phosphate starvation treatments:

  • Establish clear Pi-sufficient (+Pi) and Pi-deficient (-Pi) growth conditions

  • For Arabidopsis, standard +Pi is typically 1-2 mM phosphate while -Pi ranges from 0-50 μM

  • Monitor physiological responses (root architecture, anthocyanin accumulation) to confirm effectiveness of treatment

• PHR1 target gene analysis:

  • Design primers for key PHR1 target genes including PHO1, PHT1, PHF1, and RNS1

  • When analyzing PHR1 binding to promoters, focus on the P1BS cis-element (GNATATNC) sequence

  • Use ChIP assays to assess PHR1 binding to target promoters under different phosphate conditions

• Jasmonate signaling interaction studies:

  • Include methyl jasmonate (MeJA) treatments to investigate cross-talk between phosphate and jasmonate signaling

  • Focus on LOX2 and LOX3 expression, as PHR1 directly regulates these jasmonate-responsive genes

  • Use both Pi-sufficient and Pi-deficient conditions with and without MeJA treatment

• Integration of multiple techniques:

  • Combine protein detection (Western blot using anti-PHR1 antibodies) with:

    • Gene expression analysis (qRT-PCR for target genes)

    • Protein-DNA interaction studies (ChIP, EMSA)

    • Protein-protein interaction assays (Co-IP, Y2H) to assess PHR1 interaction with JAZ proteins

How can I use PHR1 antibodies to investigate regulatory mechanisms in both plant and mammalian systems?

PHR1 antibodies can be leveraged to investigate regulatory mechanisms through these experimental approaches:

• Post-translational modification analysis:

  • Use phospho-specific antibodies or general PHR1 antibodies followed by phosphatase treatment to detect phosphorylation status

  • Employ immunoprecipitation with PHR1 antibodies followed by mass spectrometry to identify modifications and interaction partners

• Protein-protein interaction studies:

  • Use PHR1 antibodies for co-immunoprecipitation (Co-IP) to identify interaction partners

  • For plant PHR1: Focus on interactions with JAZ proteins that modulate PHR1 activity

  • For mammalian MYCBP2/PHR1: Investigate interactions with ubiquitination machinery components

• Subcellular localization:

  • Perform cell fractionation followed by Western blot with PHR1 antibodies to track nuclear vs. cytoplasmic distribution

  • Use PHR1 antibodies for immunofluorescence to visualize localization changes in response to stimuli

  • For plant PHR1: Monitor nuclear accumulation under phosphate starvation conditions

  • For mammalian MYCBP2/PHR1: Track changes in neuronal cells during development

• Chromatin association dynamics:

  • Employ ChIP-seq with PHR1 antibodies to map genome-wide binding sites

  • For plant PHR1: Compare binding profiles under normal and phosphate starvation conditions

  • Focus on P1BS elements (GNATATNC) for plant PHR1 binding sites

What methodologies can address antibody cross-reactivity challenges when studying PHR1?

When facing cross-reactivity challenges with PHR1 antibodies, implement these methodological solutions:

• Antibody validation approaches:

  • Perform side-by-side testing with positive controls (recombinant PHR1) and negative controls (PHR1 knockout/mutant samples)

  • Use competing peptides to confirm specificity, as demonstrated in immunogen affinity purification methods

  • Consider using multiple antibodies targeting different epitopes to cross-validate findings

• Sample preparation refinements:

  • Optimize protein extraction protocols to minimize contamination with cross-reactive proteins

  • For plant samples: Use specific extraction buffers optimized for nuclear proteins when targeting PHR1

  • For mammalian samples: Consider subcellular fractionation to enrich for PHR1/MYCBP2

• Experimental design modifications:

  • Include parallel experiments with genetic tools (PHR1 knockout/knockdown models)

  • Use recombinant PHR1 protein as a standard curve for quantitative assays

  • Implement alternative detection methods (such as mass spectrometry) to confirm antibody-based findings

• Data analysis considerations:

  • When analyzing Western blots, be aware of the expected molecular weight for your specific PHR1 target:

    • Plant PHR1 in monocots: ~33 kDa

    • Mammalian MYCBP2/PHR1: 513.6 kDa

  • Document all bands detected and compare with literature reports

How do detection methods for plant PHR1 differ from those for mammalian PHR1/MYCBP2?

The detection methods for plant PHR1 and mammalian PHR1/MYCBP2 differ in several critical aspects due to their distinct molecular characteristics:

When designing experiments, researchers must account for these differences by:

• Adjusting protein extraction protocols to accommodate the different cellular localizations and biochemical properties

• Modifying Western blot protocols to account for vast differences in molecular weight

• Selecting appropriate positive controls specific to each system

• Utilizing system-specific functional assays to validate antibody performance in biological contexts

What are the recommended approaches for analyzing PHR1 in non-model organisms?

When investigating PHR1 in non-model organisms, consider these methodological approaches:

• Antibody selection strategy:

  • Begin with antibodies raised against conserved regions of PHR1

  • For plant non-model organisms: Consider antibodies that recognize monocot PHR1 (for cereal crops) or dicot PHR1 (for non-grass species)

  • For non-model animals: Use antibodies against highly conserved regions of MYCBP2/PHR1

  • Validate antibody cross-reactivity using Western blot with recombinant PHR1 from your species of interest

• Sequence homology analysis:

  • Perform sequence alignment of PHR1 from your species with known PHR1 sequences

  • Identify conserved domains that might be recognized by available antibodies

  • For plants: Focus on the conserved MYB-CC domain that characterizes PHR transcription factors

  • Design custom peptide antibodies targeting conserved regions if commercial options show poor cross-reactivity

• Functional validation approaches:

  • For plants: Test Pi starvation responses and measure PSI gene expression

  • Examine P1BS element (GNATATNC) binding using ChIP or EMSA with your species' protein extracts

  • Verify PHR1 function through genetic approaches (RNAi, CRISPR) when transformation protocols exist

• Species-specific optimization:

  • Adjust protein extraction buffers based on tissue composition and secondary metabolites

  • Modify immunoprecipitation protocols to account for species-specific protein interactions

  • Develop species-appropriate positive and negative controls for antibody validation

How can PHR1 antibodies be used to investigate evolutionary conservation of phosphate signaling?

PHR1 antibodies provide valuable tools for comparative studies of phosphate signaling evolution across species:

• Cross-species reactivity testing:

  • Screen PHR1 antibodies against protein extracts from multiple species

  • Document specific band patterns and molecular weights across taxonomic groups

  • Example approach: Test Arabidopsis PHR1 antibodies against other Brassicaceae, then extend to more distant plant families

  • For animal PHR1/MYCBP2: Compare detection patterns across vertebrate and invertebrate models

• Comparative phosphate starvation experiments:

  • Subject diverse species to standardized phosphate starvation protocols

  • Use PHR1 antibodies to monitor protein expression, localization, and post-translational modifications

  • Correlate PHR1 behavior with species-specific phosphate adaptation strategies

  • Compare P1BS element conservation in PSI gene promoters across species

• Structural conservation analysis:

  • Use immunoprecipitation with PHR1 antibodies followed by mass spectrometry

  • Identify conserved post-translational modification sites and interaction partners

  • Map conservation of functional domains recognized by specific PHR1 antibodies

  • Create evolutionary profiles of PHR1 regulatory mechanisms

• Data integration approach:

  • Combine antibody-based detection with:

    • Genomic analysis of PHR1 and target gene sequences

    • Transcriptomic profiling of phosphate responses

    • Phosphoproteomic analysis of signaling cascades

  • Develop evolutionary models of phosphate signaling pathway conservation and divergence

How do I design ChIP experiments to study PHR1 binding to target gene promoters?

Designing effective ChIP experiments for PHR1 binding studies requires careful planning:

• Experimental conditions:

  • Compare PHR1 binding under normal and phosphate-deficient conditions

  • Include additional treatments relevant to your research question (e.g., MeJA treatment to study jasmonate signaling interactions)

  • Use appropriate time points to capture dynamic binding events

• ChIP protocol optimization:

  • Crosslinking: Standard 1% formaldehyde for 10-15 minutes, but optimize for your tissue type

  • Sonication: Adjust conditions to achieve chromatin fragments of 200-500 bp

  • Immunoprecipitation: Use 5-10 μg of anti-PHR1 antibody per sample

  • Include no-antibody and IgG controls to assess background

  • For plant PHR1: Focus on regions containing the P1BS element (GNATATNC)

• Target selection:

  • Primary targets: Include known PHR1-regulated genes (PHO1, PHT1, PHF1, RNS1)

  • For jasmonate signaling studies: Include LOX2 and LOX3 promoter regions

  • Design multiple primer pairs covering P1BS elements and control regions

  • Include negative control regions (genes not regulated by PHR1)

• Data analysis:

  • Normalize enrichment to input samples

  • Compare enrichment at target regions versus control regions

  • Assess enrichment changes across experimental conditions

  • Correlate binding with gene expression changes

• Validation approaches:

  • Confirm binding sites with electrophoretic mobility shift assays (EMSA)

  • Validate functional significance through reporter gene assays with wild-type and mutated P1BS elements

  • Perform ChIP-seq for genome-wide binding site identification

What methods can be used to study PHR1 protein-protein interactions in vivo?

To investigate PHR1 protein-protein interactions in vivo, consider these methodological approaches:

• Co-immunoprecipitation (Co-IP) with PHR1 antibodies:

  • Use PHR1 antibodies to pull down protein complexes from tissue/cell lysates

  • Perform western blot analysis to detect specific interaction partners

  • For plant PHR1: Focus on interactions with JAZ proteins that modulate PHR1 activity

  • For mammalian PHR1/MYCBP2: Investigate interactions with ubiquitination machinery

• Proximity-based labeling techniques:

  • Generate PHR1 fusion constructs with BioID or APEX2

  • Express in relevant cell types or plant tissues

  • Activate labeling under specific conditions (e.g., phosphate starvation)

  • Purify biotinylated proteins and identify by mass spectrometry

• Förster resonance energy transfer (FRET) microscopy:

  • Create fluorescent protein fusions of PHR1 and potential interaction partners

  • Express in appropriate cell types or plant tissues

  • Measure FRET signals under different experimental conditions

  • Quantify interaction dynamics in response to phosphate availability or jasmonate treatment

• Split-reporter complementation assays:

  • Use split-YFP, split-luciferase, or split-ubiquitin systems

  • Generate fusion constructs with PHR1 and candidate interactors

  • Express in appropriate experimental system

  • Monitor reporter reconstitution under different conditions

  • For plant studies: Test PHR1 interaction with JAZ proteins under phosphate starvation and normal conditions

• Validation and controls:

  • Include appropriate negative controls (non-interacting proteins)

  • Validate key interactions using multiple independent techniques

  • Correlate protein interactions with functional outcomes

  • Perform domain mapping to identify specific interaction interfaces

How can I quantitatively measure changes in PHR1 protein levels in response to environmental stimuli?

To quantitatively assess PHR1 protein dynamics in response to environmental stimuli, implement these methodological approaches:

• Quantitative Western blot analysis:

  • Use PHR1 antibodies with fluorescent or infrared secondary antibodies for linear detection

  • Include recombinant PHR1 standards at known concentrations for calibration

  • Normalize to appropriate loading controls (actin, tubulin, GAPDH)

  • Use image analysis software to quantify band intensities

  • Include biological and technical replicates for statistical analysis

• ELISA-based approaches:

  • Develop sandwich ELISA using PHR1 antibodies

  • Generate standard curves with recombinant PHR1 protein

  • Process samples under standardized conditions

  • Measure PHR1 levels across time points and treatments

  • Calculate absolute protein concentrations based on standard curves

• Mass spectrometry-based quantification:

  • Use targeted approaches such as selected reaction monitoring (SRM) or parallel reaction monitoring (PRM)

  • Develop specific PHR1 peptide transitions for quantification

  • Include isotopically labeled peptide standards for absolute quantification

  • Monitor multiple PHR1 peptides and post-translational modifications

  • Correlate protein abundance with phosphate status or other environmental variables

• Experimental design considerations:

  • For phosphate starvation studies: Include multiple time points to capture dynamic responses

  • For comparative analyses: Standardize growth conditions and sampling procedures

  • Include appropriate controls for each environmental treatment

  • Document physiological responses to confirm effectiveness of treatments

  • For plant studies: Monitor anthocyanin accumulation and PSI gene expression as markers of phosphate starvation

• Data presentation and analysis:

  • Present relative fold changes in PHR1 levels compared to control conditions

  • Perform appropriate statistical tests (t-test, ANOVA) to establish significance

  • Correlate PHR1 protein levels with functional outputs (gene expression, metabolite levels)

  • Consider systems biology approaches to integrate protein abundance data with transcriptomic and metabolomic datasets

How do I address non-specific binding when using PHR1 antibodies?

When encountering non-specific binding with PHR1 antibodies, implement these methodological solutions:

• Optimization of blocking conditions:

  • Test different blocking agents (5-10% milk, BSA, commercial blockers)

  • Extend blocking time (2-3 hours or overnight at 4°C)

  • Add 0.1-0.3% Tween-20 to reduce hydrophobic interactions

  • For mammalian PHR1/MYCBP2 detection: Consider using BSA instead of milk to reduce non-specific binding

• Antibody dilution and incubation adjustments:

  • Test serial dilutions of primary antibody (1:500 to 1:5000)

  • Optimize incubation conditions (1 hour at room temperature vs. overnight at 4°C)

  • Include 0.05-0.1% detergent in antibody dilution buffer

  • For problematic samples: Consider using antibody dilution buffers with protein additives (0.1-1% BSA)

• Stringency washing protocol:

  • Increase wash buffer stringency (higher salt concentration or detergent)

  • Extend washing times and number of washes

  • Use wash buffers with additives to reduce non-specific interactions

  • Implement temperature-controlled washing steps (e.g., 37°C washes)

• Sample preparation refinements:

  • Improve protein extraction and purification methods

  • Implement pre-clearing steps with protein A/G beads

  • Use detergent-compatible protein assays to ensure consistent loading

  • Consider subcellular fractionation to enrich for PHR1-containing compartments

• Controls and validation:

  • Perform peptide competition assays to identify specific vs. non-specific bands

  • Include PHR1 knockout/knockdown samples as negative controls

  • Use purified recombinant PHR1 protein as a positive control

  • Document all consistent bands and compare with literature reports

What are effective strategies for detecting low abundance PHR1 protein?

To enhance detection of low abundance PHR1 protein, implement these methodological strategies:

• Sample enrichment techniques:

  • Perform nuclear extraction for transcription factor enrichment

  • Use immunoprecipitation to concentrate PHR1 before Western blot analysis

  • Implement subcellular fractionation to reduce sample complexity

  • For plant PHR1: Induce expression with phosphate starvation before extraction

• Signal enhancement methods:

  • Use highly sensitive ECL substrates (femto-level detection systems)

  • Employ biotin-streptavidin amplification systems

  • Consider tyramide signal amplification for immunofluorescence

  • Increase exposure times while monitoring background levels

  • Use cooled CCD cameras for sensitive, quantitative detection

• Antibody selection and optimization:

  • Test multiple antibodies targeting different PHR1 epitopes

  • Consider using concentrated antibody preparations

  • Optimize antibody incubation time (overnight at 4°C)

  • Use signal enhancing polymers conjugated to secondary antibodies

• Protocol modifications:

  • Increase protein loading (50-100 μg per lane)

  • Reduce transfer buffer methanol content for more efficient transfer of large proteins

  • Use PVDF membranes instead of nitrocellulose for higher protein binding capacity

  • Implement extended blocking (overnight) to reduce background

• Alternative detection approaches:

  • Consider multiplexed detection systems with fluorescent secondary antibodies

  • Use proximity ligation assays to detect PHR1 interactions with enhanced sensitivity

  • Implement digital droplet PCR for quantification of PHR1 transcripts as a complement to protein detection

  • Use mass spectrometry with targeted approaches for very low abundance detection